Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 34

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 34
---
 approximately 36.9% of the outstanding shares of Common Stock. Although the COD does not contain the adjustments to the Alternate Conversion procedures contained in the terms of the Company’s outstanding Series A Preferred Stock or Series C Preferred Stock applicable when the Alternate Conversion Price is less than the Floor Price, the Floor Price does not apply to adjustments in connection with the issuance of securities at prices below the then -currentconversion price. As a result, following such issuances, the conversion price may be adjusted to a price below the Floor Price, resulting in the issuance of more than 195million shares of Common Stock. In addition, under the terms of the Series E Preferred Stock, an October 2025 Investor may not convert the Series E Preferred Stock to the extent (but only to the extent) such October 2025 Investor or any of its affiliates would beneficially own a number of shares of Common Stock which would exceed 4.99%, or, at the election of the October 2025 Investor, a number of shares of Common Stock which would exceed 9.99%. October 2025 Private Placement In October 2025, the Company consummated the October 2025 Private Placement of 3,816 shares of Series E Preferred Stock pursuant to the October 2025 Securities Purchase Agreement, dated October 14, 2025, as amended pursuant to the Amendment No. 1 to the Securities Purchase Agreement, dated October 15, 2025 (collectively, the “October 2025 Securities Purchase Agreement”), for aggregate proceeds of approximately $2.25 million, and agreed to issue up to 5,934 additional shares of Series E Preferred Stock for proceeds of up to $4.75 million at one or more additional closings. Each additional closing under the October 2025 Securities Purchase Agreement is subject to a mutual option of the Company and certain October 2025 Investors and satisfaction of customary closing conditions. Description of Securities See “ Description of Capital Stock” for a description of the Series E Preferred Stock. Impact on Stockholders of Approval or Disapproval of this Proposal If this proposal is approved, existing stockholders will suffer dilution in ownership interests and voting rights as a result of the issuance of shares of Common Stock upon the conversion of the shares of Series E Preferred Stock. Assuming the issuance of all shares of Common Stock upon conversion of the Series E Preferred Stock, the October 2025 Investors would own approximately 2.3million shares of Common Stock, assuming conversion at the initial conversion price of $4.